Home > HP (current issue) > News and features / News Centre | Search

PJ Online homeHospital Pharmacist
2006;13:38
February 2006

Hospital Pharmacist back issues

News summary


Improvements needed in NHS cancer plan

Clear inequalities in cancer outcome remain between socioeconomic groups, with higher mortality rates in deprived areas and higher survival rates in London and the South.

This is a finding of a new report by the House of Commons Committee of Public Accounts on the progress of the NHS cancer plan (PDF 830K).

The plan, published in 2000, established 34 cancer networks in England which involve collaborative working between strategic health authorities, acute and primary care trusts, the voluntary sector and local authorities, to improve provision of cancer services to patients.

However, the new report found that relationships between constituent organisations can be difficult and that commissioning of cancer services is not sufficiently joined up in some network areas.

It states that a third of cancer networks have, at best, an adequate relationship with the primary care trusts that provide their funding, and that the creation of NHS foundation trusts brings the risk of more limited partnership working.

The report says that 30 per cent of networks visited by the National Audit Office did not have comprehensive plans for providing cancer services in their area.

Increased funding for cancer services is reaching the front line and being spent directly on funding new drugs, staffing and new services, although staffing of some posts is proving to be difficult. The report states that 25 per cent of lead pharmacist positions that have been created in cancer networks remain unfilled.

The report also highlights variations in the availability of cancer drugs. It states that unacceptably wide variations in use of National Institute for Health and Clinical Excellence approved cancer drugs persist between different parts of the country. For example, the use of trastuzumab (Herceptin) for metastatic breast cancer in eligible women ranged from 90 per cent to fewer than ten per cent.

The report recommends better monitoring of performance against cancer plan targets, and says that cancer networks should make clear in their delivery plans how inequalities are being addressed. It recommends that the cancer plan is updated to take into account the NHS structural changes since it was published.

Back to Top


©The Pharmaceutical Journal